PMID- 21938468
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121002
LR  - 20211020
IS  - 0920-9069 (Print)
IS  - 1573-0778 (Electronic)
IS  - 0920-9069 (Linking)
VI  - 64
IP  - 1
DP  - 2012 Jan
TI  - Clinical reagents of GM-CSF and IFN-alpha induce the generation of functional chronic 
      myeloid leukemia dendritic cells in vitro.
PG  - 75-81
LID - 10.1007/s10616-011-9393-2 [doi]
AB  - Dendritic cells (DCs) have been successfully induced in vitro from chronic 
      myeloid leukemia (CML) cells, which may provide a promising immunotherapeutic 
      protocol for CML. To facilitate the optimization of DCs-based vaccination 
      protocols, we investigated the efficiency of in vitro generation of DCs from bone 
      marrow mononuclear cells of CML patients by clinical reagents of GM-CSF and 
      IFN-alpha. Bone marrow mononuclear cells were isolated from eight CML patients and 
      CML-DCs were generated in the presence of different cytokines (Group A: GM-CSF 
      for research and IL-4 for research; Group B: GM-CSF for injection and IFN-alpha for 
      injection) in RMPI-1640 medium containing 10% human AB serum. After 8 days, the 
      morphologic features of CML-DCs were observed and their immunophenotypes were 
      analyzed by flow cytometry. The activity of CML-DCs was determined by evaluating 
      their ability to stimulate allogeneic mixed lymphocyte reaction (allo-MLR) and 
      anti-leukemic cytotoxic T lymphocytes (CTLs). The culture protocols were 
      successful in generating functional CML-DCs from all the CML patients as 
      evidenced by the significant upregulation of CD80, CD86, CD83 HLA-DR and CD1a 
      compared to pre-cultured (p < 0.05), and increased allogeneic T cell stimulating 
      proliferation capacity (p < 0.05). CML-DCs could stimulate a specific 
      anti-leukemia response. In summary, we demonstrate that the combination of 
      clinical reagents GM-CSF and IFN-alpha induced the generation of DCs that have the 
      ability to stimulate a specific anti-leukemia CTLs response in vitro, indicating 
      their feasibility for clinical vaccination protocols for CML patients.
FAU - Weng, Kaizhi
AU  - Weng K
AD  - Zhangzhou Municipal Hospital, Affiliated to Fujian Medical University, Zhangzhou, 
      363000, People's Republic of China, lqlrandywkz@163.com.
FAU - Xie, Xiaobao
AU  - Xie X
FAU - Qiu, Guoqiang
AU  - Qiu G
FAU - Gu, Weiying
AU  - Gu W
LA  - eng
PT  - Journal Article
DEP - 20110922
PL  - United States
TA  - Cytotechnology
JT  - Cytotechnology
JID - 8807027
PMC - PMC3261453
EDAT- 2011/09/23 06:00
MHDA- 2011/09/23 06:01
PMCR- 2013/01/01
CRDT- 2011/09/23 06:00
PHST- 2011/06/04 00:00 [received]
PHST- 2011/09/05 00:00 [accepted]
PHST- 2011/09/23 06:00 [entrez]
PHST- 2011/09/23 06:00 [pubmed]
PHST- 2011/09/23 06:01 [medline]
PHST- 2013/01/01 00:00 [pmc-release]
AID - 9393 [pii]
AID - 10.1007/s10616-011-9393-2 [doi]
PST - ppublish
SO  - Cytotechnology. 2012 Jan;64(1):75-81. doi: 10.1007/s10616-011-9393-2. Epub 2011 
      Sep 22.